Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study

Jennifer Molano1, Bradley Boeve, Tanis Ferman

  • 1Mayo Clinic, Rochester, MN 55905, USA.

Insights

Rapid eye movement sleep behaviour disorder (RBD) and mild cognitive impairment (MCI) can precede dementia with Lewy body disease (DLBD). RBD and MCI may indicate brainstem and cerebral Lewy body disease.

Area of Science:

  • Neurology
  • Neuroscience
  • Gerontology

Background:

  • Limited data exist on the link between Lewy body disease (LBD) and mild cognitive impairment (MCI) syndromes.
  • Autopsy-proven LBD cases with prior MCI diagnoses are rare, necessitating further investigation.
  • Understanding the prodromal stages of LBD is crucial for early diagnosis and intervention.

Purpose of the Study:

  • To investigate the clinical characteristics and progression of individuals with autopsy-proven Lewy body disease (LBD) who experienced mild cognitive impairment (MCI).
  • To assess the prevalence and significance of rapid eye movement sleep behaviour disorder (RBD) in the MCI prodromal phase of LBD.
  • To explore the relationship between MCI subtypes, cognitive profiles, and neuropathological findings in LBD.

Main Methods:

  • Retrospective analysis of Mayo Clinic databases for patients diagnosed with MCI between 1996 and 2008, followed prospectively, and confirmed with autopsy-proven LBD.
  • Specific assessment of rapid eye movement sleep behaviour disorder (RBD) and determination of MCI subtypes based on clinical and neuropsychological criteria.
  • Magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (MRS) were used to evaluate hippocampal volumes, atrophy rates, and neurochemical changes.

Main Results:

  • Eight subjects with autopsy-proven LBD and prior MCI were identified; seven progressed to dementia with Lewy bodies (DLBD).
  • Rapid eye movement sleep behaviour disorder (RBD) preceded cognitive symptoms and MCI diagnosis by a median of 10 and 12 years, respectively.
  • Commonly affected cognitive domains included attention, executive functioning, and visuospatial skills; hippocampal volumes were generally normal, but elevated choline/creatine ratios were observed.

Conclusions:

  • Mild cognitive impairment (MCI) in Lewy body disease (LBD) can manifest with diverse cognitive patterns and subtypes.
  • The presence of rapid eye movement sleep behaviour disorder (RBD) alongside MCI strongly suggests underlying brainstem and cerebral LBD.
  • RBD and MCI are significant indicators of prodromal Lewy body disease, highlighting their importance in clinical assessment.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.